# KelSie Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kelsie-biotech

- Industry: Healthcare
- Headquarters: Englewood, US
- Website: www.kel-sie.com
- Total disclosed funding: $5M
- Latest round: Series A (May 31, 2019)
- Investors on record: 2

## About

KelSie Biotech, LLC is a biotechnology company specializing in innovative formulation services aimed at enhancing drug delivery through advanced technologies.Founded in 2017 and headquartered in Englewood, US, KelSie Biotech, LLC focuses on developing enhanced drug delivery systems. The company has successfully secured its Series A funding round in May 2019, raising USD 5 mn led by Salveo Capital with participation from Arcadian Capital. Ben Kaanta serves as the CEO.KelSie Biotech specializes in innovative formulation services aimed at enhancing drug delivery through advanced technologies such as their Genesis CAN-BD formulation. Their core offerings include a range of delivery systems including deep lung delivery, nasal sprays, sublingual wafers, and topical applications. Each product is designed to address specific therapeutic needs, allowing for more effective administration of medications. The company primarily serves pharmaceutical developers and healthcare providers in North America, Europe, and select markets in Asia, catering to a diverse client base that includes research institutions, biotech firms, and pharmaceutical companies focused on improving patient outcomes.KelSie Biotech's revenue model is structured around B2B interactions, focusing on partnerships and collaborations with pharmaceutical companies and research institutions. The firm engages in direct transactions for its formulation services, typically structured as project-based agreements or long-term partnerships based on specific client needs. Clients may opt for comprehensive packages that encompass formulation development, testing, and trial design, allowing for tailored solutions to meet unique requirements.In May 2019, KelSie Biotech, LLC raised USD 5 mn in Series A funding, which will be utilized to support the development of upcoming products and services. The company is targeting expansion into new geographic regions, particularly in key markets across Asia, with plans to initiate this expansion by 2023. KelSie Biotech aims to enhance its product offerings and reach a broader client base through these strategic initiatives.

## Funding rounds

- Series A, May 31, 2019, $5M — Salveo Capital, Arcadian Capital

## Investors

- Salveo Capital (https://capitalatlas.ai/funds/salveo-capital) — Series A
- Arcadian Capital (https://capitalatlas.ai/funds/arcadian-capital) — Series A